文献速递心脏核医学骨显像与常规 SPECT

利用骨扫描结合超声心动图和临床相关性估算澳大利亚亚人群中转甲状腺素蛋白(ATTR)心脏淀粉样变的患病率

Estimation of prevalence of transthyretin (ATTR) cardiac amyloidosis in an Australian subpopulation using bone scans with echocardiography and clinical correlation.
PubMed 文献 · J Nucl Cardiol · 2020-05-08

在澳大利亚亚人群中,基于非心脏适应症骨扫描的盲法回顾,心脏摄取阳性(≥肋骨且H/WB>0.0388)在<65岁者为0%,≥85岁男性达6.15%;HMDP阳性者均有室间隔增厚,H/WB与左室质量正相关、与左室射血分数负相关;MDP扫描阳性仅1/3446例。

要点

  • <65岁者阳性率为0%,≥85岁男性阳性率6.15%。
  • HMDP阳性者均有超声室间隔增厚,H/WB与左室质量正相关。

核心结论

  • 在该澳大利亚亚人群中,符合心脏ATTR的骨扫描阳性患病率在<65岁者为0%,随年龄增长在≥85岁男性中达6.15%。
  • HMDP摄取量与超声心动图所示更晚期心脏受累特征相关。
  • MDP在ATTR中似乎无用。

研究设计与样本

  • 回顾性分析因非心脏适应症接受锝-99m HMDP或锝-99m MDP骨扫描的患者,共纳入6918例。
  • 进行盲法图像审阅,阳性定义为心脏摄取≥肋骨且心脏/全身比值(H/WB)>0.0388。
  • 回顾超声心动图和临床记录。

主要发现

  • HMDP扫描阳性15/3472例(14男1女):<65岁者0例;≥65岁男性1.44%、女性0.17%;≥85岁男性6.15%、女性1.69%。
  • MDP扫描阳性仅1/3446例。
  • 所有HMDP阳性患者超声心动图均显示室间隔壁增厚。
  • H/WB与左室质量正相关,与左室射血分数负相关。
  • 无个体其阳性扫描有ATTR以外的解释。

关键数值与推荐

  • 阳性标准:心脏摄取≥肋骨且H/WB>0.0388。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Bone scans differentiate transthyretin (ATTR) cardiac amyloidosis from light chain amyloidosis and other causes of increased left ventricular (LV) wall thickness. We examined the prevalence and implications of cardiac uptake in the general population. METHODS: Patients were included based on having undertaken a bone scan for non-cardiac indications using Technetium 99m hydroxymethylene diphosphonate (HMDP) or Technetium 99m methylene diphosphonate (MDP). Blinded image review was undertaken. Positive was defined as cardiac uptake ≥ rib AND heart/whole body ratio (H/WB) > 0.0388. Echocardiography and clinical records were reviewed. RESULTS: 6918 patients were included. 15/3472 HMDP scans were positive (14 males, 1 female): none in individuals aged < 65; 1.44% in males and 0.17% in females ≥ 65; 6.15% in males and 1.69% in females ≥ 85. Only 1/3446 MDP scans were positive. All HMDP positive patients had increased septal wall thickness on echocardiography. H/WB correlated positively with LV mass, and negatively with LV ejection fraction. No individual had an explanation other than ATTR for their positive scan. CONCLUSION: In this Australian subpopulation, the prevalence of positive bone scans consistent with cardiac ATTR is 0% in individuals aged < 65. Prevalence increased with age, reaching 6.15% in men ≥ 85. The amount of HMDP uptake correlated with echocardiographic features of more advanced cardiac involvement. MDP does not appear useful in ATTR.

来源:J Nucl Cardiol,查看原文。版权归原作者所有。

引用

  1. Cuscaden C, Ramsay SC, Prasad S, et al. Estimation of prevalence of transthyretin (ATTR) cardiac amyloidosis in an Australian subpopulation using bone scans with echocardiography and clinical correlation. J Nucl Cardiol. 2020. PMID: 32385832. doi:10.1007/s12350-020-02152-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。